Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

Sana Biotechnology Inc (SANA)

Sana Biotechnology Inc (SANA)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
1.7600 +0.2300 (+15.03%) 04/11/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 1.7401 -0.0199 (-1.13%) 19:42 ET
Quote Overview for Fri, Apr 11th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.4900
Day High
1.7900
Open 1.5300
Previous Close 1.5300 1.5300
Volume 5,517,100 5,517,100
Avg Vol 5,110,960 5,110,960
Stochastic %K 30.60% 30.60%
Weighted Alpha -88.04 -88.04
5-Day Change +0.2800 (+18.92%) +0.2800 (+18.92%)
52-Week Range 1.2600 - 10.5000 1.2600 - 10.5000
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 396,044
  • Shares Outstanding, K 225,025
  • Annual Sales, $ 0 K
  • Annual Income, $ -266,760 K
  • EBIT $ -273 M
  • EBITDA $ -255 M
  • 60-Month Beta 1.78
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.36

Options Overview Details

View History
  • Implied Volatility 230.06% ( +85.79%)
  • Historical Volatility 143.23%
  • IV Percentile 79%
  • IV Rank 21.18%
  • IV High 833.42% on 01/06/25
  • IV Low 67.95% on 10/07/24
  • Put/Call Vol Ratio 0.13
  • Today's Volume 563
  • Volume Avg (30-Day) 691
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 24,094
  • Open Int (30-Day) 25,797

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.21
  • Number of Estimates 4
  • High Estimate -0.19
  • Low Estimate -0.24
  • Prior Year -0.32
  • Growth Rate Est. (year over year) +34.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2600 +39.68%
on 04/04/25
Period Open: 2.7500
3.0050 -41.43%
on 03/17/25
-0.9900 (-36.00%)
since 03/11/25
3-Month
1.2600 +39.68%
on 04/04/25
Period Open: 3.6600
4.0100 -56.11%
on 01/13/25
-1.9000 (-51.91%)
since 01/10/25
52-Week
1.2600 +39.68%
on 04/04/25
Period Open: 9.3600
10.5000 -83.24%
on 05/06/24
-7.6000 (-81.20%)
since 04/11/24

Most Recent Stories

More News
Mineralys, Sana, Aeon: These 3 Biotech Stocks Saw The Sharpest Retail Interest Spike In Q1

Three small-cap stocks have intrigued Stocktwits users the most among the biotech sector this year, thanks to promising data from clinical trials and a leadership shuffle.

SANA : 1.7600 (+15.03%)
MLYS : 13.40 (+9.93%)
AEON : 0.4000 (-2.27%)
Sana: Q4 Earnings Snapshot

Sana: Q4 Earnings Snapshot

SANA : 1.7600 (+15.03%)
Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

SANA : 1.7600 (+15.03%)
Sana Biotechnology to Present at the Cowen 45th Annual Health Care Conference

SANA : 1.7600 (+15.03%)
Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Why

Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.

KAPA : 1.0100 (+2.02%)
SANA : 1.7600 (+15.03%)
SLXN : 0.8450 (+2.55%)
AEON : 0.4000 (-2.27%)
CRGX : 4.26 (+4.67%)
There May Still Be Time to Get in on These 3 Trending Biotechs

Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025.

AVDL : 7.68 (+7.71%)
SANA : 1.7600 (+15.03%)
IBB : 116.96 (+3.38%)
ADMA : 19.40 (+3.85%)
This Biotech Penny Stock Is Up 120% This Year. Analysts Think It Can Still Triple From Here in 2025.

With positive results from a clinical trial targeting Type 1 diabetes, Wall Street is feeling hot on this little biotech stock.

$SPX : 5,363.36 (+1.81%)
SANA : 1.7600 (+15.03%)
SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data

Shares of Sana Biotechnology SANA skyrocketed 151.5% in the past week after the company announced positive initial results from a potentially groundbreaking type 1 diabetes (T1D) study of its experimental...

CTMX : 0.5325 (+7.66%)
CSTL : 19.70 (+2.07%)
SANA : 1.7600 (+15.03%)
HALO : 60.22 (+4.37%)
Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SANA : 1.7600 (+15.03%)
Sana Biotech Stock Triples After Type 1 Diabetes Trial Wows Analysts: Retail Erupts In Excitement

Citi referred to the data as a "major scientific advance" for type 1 diabetes patients, highlighting the potential for broader applications in the allogeneic field.

SANA : 1.7600 (+15.03%)

Business Summary

Sana Biotechnology Inc. is focused on creating and delivering engineered cells as medicines for patients. The company involved in repairing and controlling genes, replacing missing or damaged cells as well as making its therapies. Sana Biotechnology Inc. is based in SEATTLE.

See More

Key Turning Points

3rd Resistance Point 2.1700
2nd Resistance Point 1.9800
1st Resistance Point 1.8700
Last Price 1.7600
1st Support Level 1.5700
2nd Support Level 1.3800
3rd Support Level 1.2700

See More

52-Week High 10.5000
Fibonacci 61.8% 6.9703
Fibonacci 50% 5.8800
Fibonacci 38.2% 4.7897
Last Price 1.7600
52-Week Low 1.2600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar